Search clinical trials for: Disease modifying antirheumatic drugs (DMARD)

Total 433519 results

Hoffmann-La Roche

Completed

Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)

Juvenile Idiopathic Arthritis
Pfizer

Completed

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Czech Republic, Turkey, Chile, Mexico, Brazil, Argentina, Spain, Slovakia, Sweden, Poland, Bulgaria, Hungary
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Completed

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis (TERRA)

Rheumatoid Arthritis

Philippines, India, Poland, Sri Lanka, United Kingdom
Barts & The London NHS Trust

Completed

Ultrasound Utility in Routine Clinical Practise

Arthritis, Rheumatoid | Ultrasonography
Diakonhjemmet Hospital
The Research Council of Norway; South-Eastern Norway Regional Health Authority

Completed

Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis (ARCTIC REWIND)

Rheumatoid Arthritis

Norway
Pfizer

Completed

Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

Rheumatoid Arthritis

Hungary, Qatar, Romania, Ukraine, China, Czech Republic, Malaysia, Thailand, Lebanon, South Africa, Philippines, Brazil, Colombia, Egypt, Jordan, Mexico, Russian Federation, Taiwan, United Arab Emirates
Amgen
Wyeth is now a wholly owned subsidiary of Pfizer; Immunex Corporation

Completed

Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy

Rheumatoid Arthritis
Biogen

Withdrawn

BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs (EMBRACE)

Rheumatoid Arthritis

Canada
Shanxi Medical University

Unknown

Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research (DCCT)

Rheumatoid Arthritis

China
Mycenax Biotech Inc.

Unknown

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis

Combination With DMARDs

Taiwan
University of Nebraska

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Rheumatoid Arthritis

United States
Zalicus

Completed

A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA

Rheumatoid Arthritis
Amgen
Wyeth is now a wholly owned subsidiary of Pfizer; Immunex Corporation

Completed

Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

Rheumatoid Arthritis
University Hospital, Montpellier

Completed

Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients (ProCOVRA)

Covid19 | Rheumatoid Arthritis

France
University of Zurich

Unknown

Effect of TNF-Inhibition Combined With Conventional DMARDs on Cervical Pannus in Patients With RA and Cervical Spine Involvement

Rheumatoid Arthritis

Switzerland
Pfizer

Completed

Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

Rheumatoid Arthritis

Denmark
Fundación Santa Fe de Bogota

Unknown

Predictive Factors for COVID-19 in Rheumatology

Covid19 | Rheumatic Diseases
Hoffmann-La Roche

Completed

A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs

Rheumatoid Arthritis

Italy
Biologics & Biosimilars Collective Intelligence...
Merck Sharp & Dohme LLC; Pfizer; AbbVie; University of Pittsburgh; Boehringer Ingelheim and other collaborators

Completed

Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis

Rheumatoid Arthritis | Psoriasis | Psoriatic Arthritis | Inflammatory Bowel Disease | Ankylosing Spondylitis
National Institute of Medical Sciences and Nutrition...

Recruiting

INCMNSZ - Rheumatoid Arthritis Cohort (IRAC)

Rheumatoid Arthritis | Early Rheumatoid Arthritis

Mexico
Mashhad University of Medical Sciences
Roche Pharma AG

Completed

Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis

DMARD Resistant Rheumatoid Arthritis

Iran, Islamic Republic of
University of Cagliari
University of Turin, Italy; University Hospital, Udine, Italy; Azienda Sanitaria... and other collaborators

Unknown

Ultrasound in Psoriatic Arthritis Treatment (UPSTREAM)

Arthritis, Psoriatic | Ultrasonography | Minimal Disease, Residual

Italy
Scios, Inc.

Completed

SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate

Arthritis, Rheumatoid
Medical University of Graz

Terminated

Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (RA-BioStop)

Rheumatoid Arthritis

Austria
AB Science

Terminated

Masitinib in Refractory Active Rheumatoid Arthritis

Rheumatoid Arthritis (RA)

Czechia
Hoffmann-La Roche

Completed

A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (RITACT)

Arthritis, Rheumatoid

Brazil
Bristol-Myers Squibb

Completed

Factors Associated With Biologic DMARD Switching

Rheumatoid Arthritis
GlaxoSmithKline
Iqvia Pty Ltd

Terminated

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (contRAst 2)

Arthritis, Rheumatoid

United States, Australia, Germany, Japan, Korea, Republic of, Poland, Bulgaria, Estonia, Hungary, Mexico, Russian Federation, Spain, Thailand, Colombia, China, Argentina, United Kingdom, France
TcLand Expression S.A.
Premier Research Group plc; Theradis pharma; Medpharmgene, Inc.

Terminated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy (PRINT)

Rheumatoid Arthritis

Canada, France, Hungary, Italy, Lithuania, Romania, Slovakia, Spain
AB Science

Completed

Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis
SetPoint Medical Corporation

Active, not recruiting

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis (RESET-RA)

Rheumatoid Arthritis

United States
University Hospital, Toulouse

Unknown

Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase

Rheumatoid Arthritis

France
DNAlytics
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Unknown

Predictive Analytics for Theranosis in RA (PAnTheRA)

Rheumatoid Arthritis

Belgium, Spain
Hoffmann-La Roche

Completed

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

Rheumatoid Arthritis

United States
Pfizer

Completed

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

Arthritis, Rheumatoid

United States, Spain, Czechia, Korea, Republic of, Poland, Chile, Mexico
Hoffmann-La Roche

Terminated

A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Finland
Hoffmann-La Roche

Completed

A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants

Rheumatoid Arthritis

Italy
Liga Panamericana de Asociaciones de Reumatologia...

Recruiting

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors (PREJAK)

Arthritis, Rheumatoid | Arthritis, Psoriatic | Spondyloarthritis

Argentina
Rottapharm Biotech

Completed

A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

Rheumatoid Arthritis, DMARD-naive and Early Disease Patients

Czechia
Diakonhjemmet Hospital
Vestre Viken Hospital Trust; University Hospital of North Norway; St. Olavs Hospital and other collaborators

Recruiting

The Norwegian Antirheumatic Drug Register (NOR-DMARD)

Inflammatory Joint Diseases

Norway
Hoffmann-La Roche

Completed

A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

Italy
Genentech, Inc.
Biogen

Completed

A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis (SUNDIAL)

Rheumatoid Arthritis
University of Leeds
Samsung Bioepis Co., Ltd.

Not yet recruiting

Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification (TEEMS)

Rheumatoid Arthritis

United Kingdom
Hoffmann-La Roche

Completed

A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

Rheumatoid Arthritis

Portugal
University of Alabama at Birmingham
Patient-Centered Outcomes Research Institute

Recruiting

RA-PRO PRAGMATIC TRIAL (RA-PROPR)

Rheumatoid Arthritis

United States, Canada
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis

Arthritis, Rheumatoid

Ukraine, Bulgaria, Canada, Czechia, Estonia, Germany, Hungary, Italy, Mexico, Poland, Russian Federation, South Africa, Spain, United Kingdom
University of Leeds

Completed

Very Early Versus Delayed Etanercept in Patients With RA (VEDERA)

Rheumatoid Arthritis

United Kingdom
Diakonhjemmet Hospital
Oslo University Hospital; University Hospital of North Norway; Helse Nord-Trøndelag... and other collaborators

Recruiting

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors (RIMRA)

Immune-related Adverse Event

Norway
Pfizer

Completed

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Costa Rica, Czech Republic, Germany, Croatia, Canada, Korea, Republic of, Spain, Bosnia and Herzegovina, Australia, Bulgaria, Mexico, Slovakia, Poland, Philippines, Chile, Denmark, Dominican Republic, Finland, T... and more
Rüdiger B. Müller
UCB Pharma

Completed

RICE: Remission by Intra-articular Injection Plus CErtolizumab (RICE)

Rheumatoid Arthritis

Switzerland

3

Subscribe